Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4
- Conditions
- Opioid-Related DisordersHeroin Dependence
- Registration Number
- NCT00000329
- Lead Sponsor
- University of Colorado, Denver
- Brief Summary
The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in buprenorphine-naloxone maintained volunteers
- Detailed Description
Ongoing study - results not available at this time
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Individuals must be at least 18 yrs of age, currently opioid dependent and meet FDA criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use.
Individuals with evidence of anti active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug/Money Preferences Subjective dose estimate Observed withdrawal rating Opioid agonist rating Opioid antagonist rating Analog rating scale for drug effects Pupil diameter Drug effect characteristics
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Colorado Health Sciences Center
🇺🇸Denver, Colorado, United States